Trial Profile
Xarelto + Acetylsalicylic Acid: Treatment Patterns and Outcomes in Patients With Atherosclerosis. A Non-interventional Study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 14 Oct 2019
Price :
$35
*
At a glance
- Drugs Aspirin (Primary) ; Rivaroxaban (Primary)
- Indications Acute coronary syndromes; Atherosclerosis; Coronary artery disease; Peripheral arterial disorders
- Focus Therapeutic Use
- Acronyms XATOA
- Sponsors Bayer
- 10 Oct 2019 Planned End Date changed from 31 Aug 2021 to 30 Jun 2021.
- 26 Nov 2018 New trial record